Bellicum Pharmaceuticals, Inc.
Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for product registration in Europe
Company on track to report final results in 2019 followed by European regulatory submission
December 1, 2018